AbbVie — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Stylus Medicinestylusmedicine.cominSeries A · May 2025 · $85M
Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.
BiotechDigital HealthMedical Devices
Michael C. Bassik, Ph.D.(Scientific Founder)inEmile Nuwaysir, Ph.D.(Chairman & Chief Executive Officer)inJason Fontenot, Ph.D.(Chief Scientific Officer)
Co-investorsBrainstorm VenturesKhosla VenturesNeva Sgr.RA CapitalTachyon Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.